-
Innovation Ranking
NewInnovation Ranking – Travere Therapeutics Inc
Travere Therapeutics Inc (Travere Therapeutics), formerly Retrophin Inc, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare...
-
Product Insights
NewNet Present Value Model: Travere Therapeutics Inc’s Pegtibatinase
Empower your strategies with our Net Present Value Model: Travere Therapeutics Inc's Pegtibatinase report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Travere Therapeutics Inc’s Sparsentan
Empower your strategies with our Net Present Value Model: Travere Therapeutics Inc's Sparsentan report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Travers Solar Phase 2 PV Park
Travers Solar Phase 2 PV Park is a solar PV project located in Alberta, Canada. The project is owned and developed by Greengate Power Corporation. The project is currently under construction. Empower your strategies with our Travers Solar Phase 2 PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
Greengate Travers MPC Solar PV Park
Greengate Travers MPC Solar PV Park is a solar PV project located in Alberta, Canada. The project is owned by Copenhagen Infrastructure Partners KS; Greengate Power Corporation and is developed by Greengate Power Corporation. The project is currently under construction. Empower your strategies with our Greengate Travers MPC Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
Net Present Value Model: Travere Therapeutics Inc’s Pegtibatinase
Empower your strategies with our Net Present Value Model: Travere Therapeutics Inc's Pegtibatinase report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Travere Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Travere Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sparsentan in Focal Segmental Glomerulosclerosis (FSGS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sparsentan in Focal Segmental Glomerulosclerosis (FSGS) Drug Details: Sparsentan (Filspari)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegtibatinase in Homocystinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegtibatinase in Homocystinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegtibatinase in Homocystinuria Drug Details: Pegtibatinase (OT-58) is under development for the treatment...
-
Product Insights
Mitochondrial Myopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Mitochondrial Myopathy - Drugs In Development, 2023’, provides an overview of the Mitochondrial Myopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mitochondrial Myopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...